BIOLASE (BIOL) Set to Announce Quarterly Earnings on Thursday

BIOLASE (NASDAQ:BIOLGet Rating) will be announcing its earnings results after the market closes on Thursday, August 11th. BIOLASE has set its FY 2022 guidance at EPS and its Q2 2022 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

BIOLASE (NASDAQ:BIOLGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The medical technology company reported ($0.81) earnings per share (EPS) for the quarter. BIOLASE had a negative return on equity of 62.40% and a negative net margin of 34.03%. The business had revenue of $10.17 million for the quarter.

BIOLASE Price Performance

BIOL stock opened at $4.74 on Thursday. The company has a quick ratio of 2.22, a current ratio of 3.34 and a debt-to-equity ratio of 0.66. BIOLASE has a 52-week low of $3.30 and a 52-week high of $23.49. The stock’s 50 day moving average is $4.48 and its two-hundred day moving average is $7.44. The company has a market capitalization of $29.27 million, a PE ratio of -2.30 and a beta of 1.48.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Lake Street Capital assumed coverage on BIOLASE in a report on Friday, May 20th. They set a “buy” rating and a $12.00 price objective on the stock. StockNews.com began coverage on BIOLASE in a research report on Thursday, July 28th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, BIOLASE currently has an average rating of “Moderate Buy” and an average price target of $41.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BIOLASE stock. State Street Corp boosted its stake in shares of BIOLASE, Inc. (NASDAQ:BIOLGet Rating) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 436,076 shares of the medical technology company’s stock after purchasing an additional 18,682 shares during the quarter. State Street Corp owned approximately 7.06% of BIOLASE worth $154,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.38% of the company’s stock.

BIOLASE Company Profile

(Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Featured Articles

Earnings History for BIOLASE (NASDAQ:BIOL)

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.